SecBot SecBot
PRESS-RELEASE ·Filed Mar 8, 2026

DYN

Dyne Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The sustained cardiopulmonary benefits strengthen the clinical and regulatory case for z-rostudirsen, potentially de-risking the path to FDA accelerated approval. Traders should monitor for upcoming interactions with the FDA and potential BLA submission timelines.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.69
T+0 close · Mar 8, 2026 · via day close
Latest settled
−2.54%
T+60 · $17.24
Vs SPY
−14.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $17.69entry
  2. T+1 · 8mo ago +11.81%α +12.00% · $19.78
  3. T+5 · 8mo ago +2.49%α +3.84% · $18.13
  4. T+20 · 7mo ago +2.66%α +5.46% · $18.16
  5. T+60 · 6mo ago −2.54%α −14.53% · $17.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functional improvements in heart and lung function for DMD patients treated with z-rostudirsen, a therapy targeting exon 51 skipping. The results, presented at the 2026 MDA Conference, suggest potential clinical benefits beyond muscle function, including cardiopulmonary improvements compared to natural history decline.

Key Facts

  • 24-month data from the DELIVER trial show improvement in lung function (FVC%p), circumferential strain, and left ventricular ejection fraction vs. expected decline in natural history.
  • Z-rostudirsen demonstrated a favorable safety profile with mostly mild or moderate TEAEs; no related serious adverse events in the registrational cohort.
  • Therapy has FDA Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for DMD amenable to exon 51 skipping.
  • Most participants at 24 months were on lower doses than the registrational 20 mg/kg, suggesting potential for even greater efficacy at full dose.
  • Data presented at a late-breaking session at the 2026 MDA Clinical & Scientific Conference.

Financial Impact

Potential path to accelerated approval; increases likelihood of future revenue and partnership interest

valuationrevenue (future)dilution (risk reduction)

Risk Factors

  • Long-term efficacy may not reflect full potential, as most patients were not continuously on the 20 mg/kg registrational dose.
  • Forward-looking statements carry inherent risk; final trial results or regulatory decisions may differ.
  • No Phase 3 data yet; approval remains contingent on confirmatory trials.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251476

Track record

54 reports on DYN

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 8, 2026